Celgene’s registrational Transcend NHL-001 study will be a big story at Ash, but the early focus falls on what has not been presented.
Daiichi Sankyo’s incredible stock market performance stands out amid the usual mixed bag of fallers and risers among biopharma’s mid- and small caps.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Sunesis’s vecabrutinib has yet to put a patient into remission, so hope rests on higher dosing of this next-generation BTK inhibitor.
A key update confirms ARQ 531 as the leading contender to treat patients who relapse on Imbruvica or Calquence.
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
Biotech’s propensity to manipulate clinical datasets to show significance where none exists must be curbed, but a plan to raise the p value threshold looks like a way of…